Pfizer Inc
-
Open
36.50
-
Previous Close
36.53
-
Volume (Avg)
21.23M (24.53M)
-
Day's Range
36.47-36.79
-
52Wk Range
31.67-39.43
-
Market Cap.
217.90B
-
Dividend Rate (Yield)
1.36 (3.71%)
-
Beta
0.90
-
Shares Outstanding
5.95B
-
P/E Ratio (EPS)
10.41 (3.52)
Top Stories
-
Global Polycystic Ovarian Syndrome Treatment Market Overview 2017-2026: Pfizer Inc., Abbott Laboratories
MarketWatch 3 days agoApr 19, 2018 (marketresearch.biz via COMTEX) -- The report on the global Polycystic Ovarian Syndrome Treatment market is an insightful reference data for established players as well as new entrants in the Global Polycystic Ovarian Syndrome Treatment market.
-
BRIEF-IBT Urges Pfizer Shareholders To Vote For Proposal 7 For Corporate Political Spending Disclosure
Reuters -
Pfizer's DMD Drug Could Spell Long-Term Trouble For Sarepta
Seeking Alpha -
Pfizer : Explore New Strategies to Maintain a Global Pharmacovigilance System by Pfizer at SMi’s 5th Drug Safety Conference
4-Traders -
Pfizer : Portage slashes taxes for Pfizer expansion expected to add 450 jobs
4-Traders 4/13/2018Portage agreed to give Pfizer Inc. a big tax break for a $465 million expansion expected to create 450 jobs within six years. Tuesday, the Portage City Council voted unanimously to approve an industrial facilities exemption that will cut property taxes in ...
-
Global Oncology Biosimilars Treatment Market Competitive landscape: Pfizer Inc, F Hoffmann-La Roche
topexaminer.com -
Michigan city approves tax breaks for Pfizer expansion plan
The Journal Record -
Fate of Pfizer Unit in Spotlight After Merck Sells Consumer Business
TheStreet.com -
Pfizer Gets Final Nod On $94M Celebrex Antitrust Settlement
Law360 -
Pfizer Invites Public to Listen to Webcast of April 26 Annual Meeting of Shareholders
The Register-Herald -
Beddow Capital Management Upped Its Holding in Pfizer (PFE) by $2.13 Million; Stephens Holding in Unitedhealth Group (UNH) Decreased by $512,160
Bibey Post -
Merck KGaA, not Pfizer, lands consumer health deal with P&G worth $4.2B
FiercePharma -
Seasonal Allergic Rhinitis Drug Market Research Analysis 2018-2025: Faes Farma, Merck & Co, Pfizer Inc, Shionogi & Co
Digital Journal -
Merck pits its pneumococcal shot against Pfizer's mammoth Prevnar in head-to-head phase 3
FiercePharma -
Pfizer, Ranbaxy Look To Dump State Claims In Lipitor MDL
Law360 5 days agoLaw360 (April 17, 2018, 7:47 PM EDT) -- Pfizer Inc. and generic-drug maker Ranbaxy Inc. asked a New Jersey federal court Monday to quash state law claims in multidistrict litigation from a group of Lipitor buyers that say the companies participated in an ...
-
Biovica International – Positive Results With DiviTum® From New Pfizer Study Presented at the AACR Congress
Virtual-Strategy -
20 years after Viagra, Pfizer seeks another miracle drug
Medical Xpress -
Pfizer plant in McPherson evacuated due to bomb threat
KWCH
